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Arterial hypertension is an independent predictor of acute myocardial infarction. Nowadays, plasma level of high-sensitive
C-reactive protein is a marker of cardiovascular risk.
The objective of the research was to evaluate plasma level of high-sensitive C-reactive protein in patients with acute
myocardial infarction and arterial hypertension depending on myocardial remodeling type.
Materials and methods. 130 patients with myocardial infarction (63 individuals with concomitant arterial hypertension and
67 individuals without it) were observed. Transthoracic echocardiogram was used. To evaluate plasma level of high-sensitive
C-reactive protein the ELISA method was applied.
Results. Plasma level of high-sensitive C-reactive protein in patients with acute myocardial infarction increased by 5.11 times
compared to the control group: (10.67 [5.43; 12.89]) mg/l and (2.09 [1.40; 4.60]) mg/l, respectively (p<0.001). In myocardial
infarction and arterial hypertension, this parameter increased by 6.57 times (to (13.73 [7.05; 15.17]) mg/l) (p<0.001), and by
1.27 times (p<0.05) as compared to patients without arterial hypertension. No differences in plasma level of high-sensitive
C-reactive protein were detected in patients with different types of left ventricular remodeling.
Conclusions. Acute myocardial infarction caused by high plasma level of high-sensitive C-reactive protein is severer in
co-existent arterial hypertension. There are no differences in blood levels of high-sensitive C-reactive protein depending on
the type of left ventricular remodeling.
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Problem statement and analysis of the
recent research
Coronary heart disease (CHD) is known to be a major cause
of death and disability in developed countries [1]. Although
CHD mortality has gradually declined over the last decades in
western countries, it still causes about one-third of all deaths
in people older than 35 years [2].
The 2016 Heart Disease and Stroke Statistics update of the
American Heart Association has recently reported that in the
USA, 15.5 million persons older than 20 years of age suffer
from CHD [3], whilst the reported prevalence increases with
age for both women and men and it has been estimated that
approximately every 42 seconds, an American suffers from
myocardial infarction (MI) [4].
High blood pressure is a major risk factor for MI and
stroke. The American Heart Association has identified it as
1 of the 7 components of ideal cardiovascular health. Based
on 2011 to 2012 data, 82.3% of children and 42.2% of adults
met these criteria [3].
Nowadays, arterial hypertension (AH) affects 1 billion
people worldwide and causes 7.5 million death every year
[5]. The National Health and Nutrition Examination Survey
(NHANES) 2009 to 2012 estimated the prevalence of hyper-
tension (age adjusted) among US adults ≥20 years of age to
be 32.6%. This equates to an estimated 80.0 million adults
≥20 years of age who have high blood pressure (38.3 million
men and 41.7 million women), extrapolated to 2012 data [3].
The age-related correlation between AH and the incidence
of MI and stroke was determined: 54% of cases of acute
disturbances of cerebral circulation and 47% of cases of acute
coronary syndrome caused by high blood pressure [6].
C-reactive protein (CRP) is a liver-derived pattern recogni-
tion molecule that increases in inflammatory states. It rapidly
increases within hours after tissue injury, and it suggests that
it is a part of the innate immune system and contributes to
host defense. Since cardiovascular disease is at least in part
an inflammatory process, CRP has been investigated in the
context of arteriosclerosis and subsequent vascular disorders.
Based on multiple epidemiological and intervention studies,
minor CRP elevation (high-sensitivity CRP (hs-CRP)) has
been shown to be associated with future major cardiovascular
risk (hs-CRP:<1 mg/L=low risk; 1-3 mg/L=intermediate risk;
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3-10 mg/L=high risk; >10 mg/L=unspecific elevation) [7].
Despite the publication of guidelines on the use of hs-CRP in
cardiovascular diseases risk prediction, there is a lack of clear
consensus regarding the optimal clinical use of hs-CRP and
its plasma levels in patients with MI and AH depending on
cardiac muscle remodeling.
The objective of the research was to evaluate plasma level
of hs-CRP in patients with acute MI and AH depending on
myocardial remodeling type.
1. Materials and methods
130 patients with ST-elevation MI were involved in the study.
There were 82 (63.07%) males and 48 (36.93%) females. The
average age was (64.68±12.59) years. All the patients were
divided into 2 groups: 63 persons with AH and 67 persons
without AH. The control group included 30 apparently healthy
individuals similar in age and sex.
Transthoracal echocardiography was performed and the
types of myocardial remodeling were calculated according to
the recommendations of the American Society of Echocardio-
graphy (ASE) and the European Association of Echocardiog-
raphy [8].
Plasma level of hs-CRP was assayed using the hs-CRP
ELISA kit (Cusabio, China).
The study was performed in accordance with the Helsinki
Declaration and Good Clinical Practice Guidelines. The study
was approved by the local ethics committee and written in-
formed consent was obtained from all the patients.
Categorical variables are presented as percentages, whereas
normally distributed continuous variables are presented as the
mean (M) and the standard error of the mean (m) and non-
normally distributed ones are presented as the median and the
interquartile range (Me (IQR)). Categorical variables were
compared by the χ2 test and continuous variables were com-
pared using the t-test or the Mann-Whitney U test. A p value
of <0.05 was considered statistically significant. All tests
were 2-sided. The analyses were performed using Statistica
software (version 12.0).
2. Results and Discussion
According to the results of echocardiography, in patients with
MI and AH, the most prevalent remodeling type was left
ventricular concentric remodeling – 24 (38.1%) persons (Table
1). Concentric hypertrophy was verified in 17 (26.9%) cases,
and eccentric hypertrophy was found in 11 (17.5%) patients.
In contrast, in patients with acute MI without AH, the most
prevalent type of left ventricular remodeling was eccentric
hypertrophy - 37 (55.2%) patients (χ2=19.88; p<0.01).
Left ventricular mass is known to predict risk of cardio-
vascular events regardless of blood pressure, other risk factors
or CHD presence [9]. Some studies showed that the classifi-
cation of left ventricular geometry enhanced the prediction of
prognosis in patients with uncomplicated essential hyperten-
sion. The 10-year mortality rate was 1%, 6%, 10% and 24%
for patients with normal, concentric remodeling, eccentric and
concentric left ventricular hypertrophy, respectively [9].
Plasma level of hs-CRP in patients with acute MI in-
creased by 5.11 times as compared to the control group: (10.67
[5.43; 12.89]) mg/l and (2.09 [1.40; 4.60]) mg/l, respectively
(p<0.001). In MI and AH, this parameter increased by 6.57
times (to (13.73 [7.05; 15.17]) mg/l) (p<0.001), and by 1.27
times (p<0.05) as compared to patients without AH. No dif-
ferences in plasma levels of hs-CRP were detected in patients
with different types of left ventricular remodeling (Table 2).
One of small cross-sectional studies determined a strong
positive correlation between serum hs-CRP and Troponin I
levels (beta = 0.509, p<0.001) in patients with acute MI. The
multiple linear regression showed that hs-CRP level could
strongly predict serum level of Troponin I within the first
24 hours after MI (beta = 0.308, the standard error = 0.080,
p<0.001). However, there was no significant correlation be-
tween the mean serum level of hs-CRP and the location of
myocardial infarction, the number of segments being involved,
left ventricular ejection fraction, and ST-segment elevation
score [10].
The other trial which included patients with MI found
that hs-CRP levels reflect the vulnerability of culprit coronary
lesions and predict adverse coronary events after primary
percutaneous transluminal coronary angioplasty or stenting
[11]. Some investigators studied serum hs-CRP levels in 205
old women with MI; they found that hs-CRP levels increased
in many patients and were independently stratified in patients
with in-hospital mortality risk [11].
3. Conclusions
Acute MI caused by high plasma level of hs-CRP is more
serious in co-existent AH. There are no differences in blood
levels of hs-CRP depending on the type of left ventricular
remodeling.
4. Prospects for further research
Prospects for further research include the study of different ef-
fects of drugs on the regression of left ventricular remodeling
after MI.
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